Secondary adherence to non-vitamin-K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands

References

• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-962
   PubMed Web of Science ®Google Scholar
• Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med 2013;274:461-8
   PubMedGoogle Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
   PubMed Web of Science ®Google Scholar
• Friberg L, Hammar N, Pettersson H, Rosenqvist M. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J 2007;28:2346-53
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, De Caterina R, et al.; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4
   Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
   PubMed Web of Science ®Google Scholar
• Karter AJ, Parker MM, Moffet HH, et al. New prescription medication gaps: a comprehensive measure of adherence to new prescriptions. Health Serv Res 2009;44:1640-61
   PubMed Web of Science ®Google Scholar
• Elseviers M, Vrijens B. Assessment of medication adherence in field research. In: Elseviers M, editor. Drug Utilization Research: Methods and Applications, 1st edn. John Wiley & Sons Inc., 2016:361-8
   Google Scholar
• Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30
   PubMed Web of Science ®Google Scholar
• Casciano JP, Dotiwala ZJ, Martin BC, Kwong WJ. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective. J Manag Care Pharm 2013;19:302-16
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Pasina L, Brucato AL, Falcone C, et al. Medication non-adherence among elderly patients newly discharged and receiving polypharmacy. Drugs Aging 2014;31:283-9
   PubMed Web of Science ®Google Scholar
• Srivastava K, Arora A, Kataria A, et al. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence 2013;7:419-34
   PubMed Web of Science ®Google Scholar
• Laliberte F, Nelson WW, Lefebvre P, et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012;29:675-90
   PubMed Web of Science ®Google Scholar
• Laliberte F, Bookhart BK, Nelson WW, et al. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient 2013;6:213-24
   PubMedGoogle Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
   PubMed Web of Science ®Google Scholar
• Comte L, Vrijens B, Tousset E, et al. Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J Pharmacokinet Pharmacodyn 2007;34:549-58
   PubMed Web of Science ®Google Scholar
• Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace 2015;17:514-23
   PubMed Web of Science ®Google Scholar
• Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost 2013;11:1295-9
   PubMed Web of Science ®Google Scholar
• Nelson WW, Song X, Coleman CI, et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin 2014;30:2461-9
   PubMed Web of Science ®Google Scholar
• Zhou M, Chang HY, Segal JB, et al. Adherence to a novel oral anticoagulant among patients with atrial fibrillation. J Manag Care Spec Pharm 2015;21:1054-62
   PubMed Web of Science ®Google Scholar
• Gorst-Rasmussen A, Skjoth F, Larsen TB, et al. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost 2015;13:495-504
   PubMed Web of Science ®Google Scholar
• Shore S, Ho PM, Lambert-Kerzner A, et al. Site-level variation in and practices associated with dabigatran adherence. JAMA 2015;313:1443-50
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace 2016;18:1150-7
   PubMed Web of Science ®Google Scholar
• McHorney CA, Peterson ED, Laliberte F, et al. Comparison of adherence to rivaroxaban versus apixaban among patients with atrial fibrillation. Clin Ther 2016;38:2477-88
   PubMed Web of Science ®Google Scholar
• Beshir SA, Chee KH, Lo YL. Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia. Int J Clin Pharm 2016;38:1182-90
   PubMed Web of Science ®Google Scholar
• McHorney CA, Crivera C, Laliberte F, et al. Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure. Curr Med Res Opin 2015;31:2167-73
   PubMed Web of Science ®Google Scholar
• Brown JD, Shewale AR, Talbert JC. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention for newly diagnosed and treatment-naive atrial fibrillation patients: an update using 2013–2014 data. J Manag Care Spec Pharm 2017;23:958-67
   PubMed Web of Science ®Google Scholar
• Borne RT, O’Donnell C, Turakhia MP, et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the Veterans Health Administration. BMC Cardiovasc Disord 2017;17:236-017-0671-6
   PubMed Web of Science ®Google Scholar
• Clemens A, Noack H, Brueckmann M, Lip GY. Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria. PLoS One 2014;9:e99276
   PubMed Web of Science ®Google Scholar
• Renda G, De Caterina R. The new oral anticoagulants in atrial fibrillation: once daily or twice daily? Vascul Pharmacol 2013;59:53-62
   PubMed Web of Science ®Google Scholar
• Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register – opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726-35
   PubMed Web of Science ®Google Scholar
• Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT; PREVEND Study Group. Pharmacy data in epidemiological studies: an easy to obtain and reliable tool. Pharmacoepidemiol Drug Saf 2002;11:379-84
   PubMed Web of Science ®Google Scholar
• Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009;25:2303-10
   PubMed Web of Science ®Google Scholar
• Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest 2010;137:263-72
   PubMed Web of Science ®Google Scholar
• Raebel MA, Schmittdiel J, Karter AJ, et al. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care 2013;51:S11-21
   Web of Science ®Google Scholar
• Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
   PubMed Web of Science ®Google Scholar
• Tsai K, Erickson SC, Yang J, et al. Adherence, persistence, and switching patterns of dabigatran etexilate. Am J Manag Care 2013;19:e325-32
   PubMed Web of Science ®Google Scholar
• Marquez-Contreras E, Martell-Carlos N, Gil-Guillen V, et al.; Compliance and Inertia Working Group; Spanish Society of Hypertension (SEH-LELHA). Therapeutic compliance with rivaroxaban in preventing stroke in patients with non-valvular atrial fibrillation: CUMRIVAFA study. Curr Med Res Opin 2016;32:2013-20
   PubMed Web of Science ®Google Scholar
• Price D, Lee AJ, Sims EJ, et al. Characteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort study. Prim Care Respir J 2013;22:161-8
   PubMedGoogle Scholar
• Hovstadius B, Petersson G. Non-adherence to drug therapy and drug acquisition costs in a national population – a patient-based register study. BMC Health Serv Res 2011;11:326-336
   PubMed Web of Science ®Google Scholar
• Ringbäck Witoft G, Ericsson Ö, Fastbom J. Health in Sweden: the National Public Health Report 2012. Scandinavian Journal of Public Health 2012;40:293-304
   PubMed Web of Science ®Google Scholar
• Visser ST, Schuiling-Veninga CC, Bos JH, et al. The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges. Expert Rev Pharmacoecon Outcomes Res 2013;13:285-92
   PubMed Web of Science ®Google Scholar
• Grymonpre R, Cheang M, Fraser M, et al. Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 2006;44:471-7
   PubMed Web of Science ®Google Scholar